Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIS513
- Development stage
- Phase 2
- Lead developer
- Serum Institute of India
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Dengushield (VIS513) is a recombinant monoclonal antibody developed by Serum Institute of India for the treatment and prevention of dengue virus infection. It is designed to neutralize all four serotypes of the dengue virus by targeting the envelope (E) protein, thereby inhibiting viral entry into host cells. The drug has undergone phase 1 clinical trials in healthy adults to assess safety and tolerability, with further development status unclear as of the latest updates. Its mechanism involves direct antiviral activity as a monoclonal antibody against dengue virus[1][2][4].
- Brand names
- Dengushield
02
Targets
DENV (Flavivirus antigens and proteins)E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on VIS513.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIS513.